Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025)
Grifols' (GRFS) quarterly Non-Current Deferred Tax Liability came in at $1.0 billion in Q4 2025, down 7.32% YoY from $1.1 billion in Q4 2024, and down 7.32% on a QoQ basis from $1.1 billion in Q4 2024.
Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $1.0 billion in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 7.32% YoY) and the FY2025 annual result came in at $1.0 billion, down 7.32% from the prior year.
- Non-Current Deferred Tax Liability declined to $1.0 billion in Q4 2025, from $1.1 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 billion in Q4 2024 to a low of $725.3 million in Q4 2021.
- A 5-year average of $985.7 million and a median of $1.1 billion in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 45.57% — and 2025, when it decreased 7.32%.
- Tracing GRFS's Non-Current Deferred Tax Liability over 5 years: stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then gained by 0.75% to $1.1 billion in 2023, then advanced by 1.67% to $1.1 billion in 2024, then declined by 7.32% to $1.0 billion in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $1.0 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Dec 31, 2017 | 457.92 Mn |
| Dec 31, 2017 | 457.92 Mn |